Cargando…

Application of preoperative ultrasound features combined with clinical factors in predicting HER2-positive subtype (non-luminal) breast cancer

BACKGROUND: Human epidermal growth factor receptor2+ subtype breast cancer has a high degree of malignancy and a poor prognosis. The aim of this study is to develop a prediction model for the human epidermal growth factor receptor2+ subtype (non-luminal) of breast cancer based on the clinical and ul...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Jin, Jin, An-qi, Zhou, Shi-chong, Li, Jia-wei, Zhi, Wen-xiang, Huang, Yun-xia, Zhu, Qian, Qian, Lang, Wu, Jiong, Chang, Cai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641182/ https://www.ncbi.nlm.nih.gov/pubmed/34856951 http://dx.doi.org/10.1186/s12880-021-00714-0

Ejemplares similares

BI-RADS 3–5 microcalcifications can preoperatively predict breast cancer HER2 and Luminal a molecular subtype
por: Cen, DongZhi, et al.
Publicado: (2017)

Clinical and prognostic profile of Her2neu positive (non-luminal) intrinsic breast cancer subtype: comparison with Her2neu positive luminal breast cancers
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Modulating cancer stemness provides luminal a breast cancer cells with HER2 positive-like features
por: Mei, Yi, et al.
Publicado: (2020)

Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)

Differences in clinical outcomes between HER2-negative and HER2-positive luminal B breast cancer
por: Kang, Byeongju, et al.
Publicado: (2023)

Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype
por: Yanagawa, Masumi, et al.
Publicado: (2012)

Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes
por: Maisonneuve, Patrick, et al.
Publicado: (2014)

Young Age Is Associated with Increased Locoregional Recurrence in Node-Positive Breast Cancer with Luminal Subtypes
por: Kim, Sang-Won, et al.
Publicado: (2017)

Luminal B breast tumors are not HER2 positive – authors' response
por: Tamimi, Rulla M, et al.
Publicado: (2008)

Negative progesterone receptor status correlates with increased risk of breast cancer recurrence in luminal B HER2-positive and -negative subtypes
por: Utsumi, Toshiaki, et al.
Publicado: (2021)

An Ultrasound Radiomics Nomogram for Preoperative Prediction of Central Neck Lymph Node Metastasis in Papillary Thyroid Carcinoma
por: Zhou, Shi-Chong, et al.
Publicado: (2020)

Analysis of tumor environmental response and oncogenic pathway activation identifies distinct basal and luminal features in HER2-related breast tumor subtypes
por: Gatza, Michael L, et al.
Publicado: (2011)

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtype
por: Bertucci, François, et al.
Publicado: (2020)

Preoperative prediction of microvascular invasion in hepatocellular carcinoma using ultrasound features including elasticity
por: Jiang, Dong, et al.
Publicado: (2023)

High Mutation Burden in ER-Positive/HER2-Negative/Luminal Breast Cancers
por: Voutsadakis, Ioannis A.
Publicado: (2022)

Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer
por: Lesniak, David, et al.
Publicado: (2013)

Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy
por: Cao, Lu, et al.
Publicado: (2016)

Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer
por: Prat, Aleix, et al.
Publicado: (2014)

Development and validation of an ultrasound-based radiomics nomogram for predicting the luminal from non-luminal type in patients with breast carcinoma
por: Wu, Jiangfeng, et al.
Publicado: (2022)

Deep learning radiomics model based on breast ultrasound video to predict HER2 expression status
por: Quan, Meng-Yao, et al.
Publicado: (2023)

EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2(+), basal-like, and HER2 intrinsic subtypes of breast cancer
por: Soysal, S D, et al.
Publicado: (2013)

HER2 status and disparities in luminal breast cancers
por: Holowatyj, Andreana N., et al.
Publicado: (2016)

The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score
por: Yang, Zheng‐Jun, et al.
Publicado: (2022)

Potential Benefits of Neoadjuvant Chemotherapy in Clinically Node-Positive Luminal Subtype(−) Breast Cancer
por: Kim, Hyung Suk, et al.
Publicado: (2019)

ER-Poor and HER2-Positive: A Potential Subtype of Breast Cancer to Avoid Axillary Dissection in Node Positive Patients after Neoadjuvant Chemo-Trastuzumab Therapy
por: Li, Jian-wei, et al.
Publicado: (2014)

BRIP1 overexpression is correlated with clinical features and survival outcome of luminal breast cancer subtypes
por: Gupta, Ishita, et al.
Publicado: (2017)

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

Correlating Tumor Stiffness with Immunohistochemical Subtypes of Breast Cancers: Prognostic Value of Comb-Push Ultrasound Shear Elastography for Differentiating Luminal Subtypes
por: Denis, Max, et al.
Publicado: (2016)

Timescale of tumor volume of a young breast cancer patient with luminal B subtype: A case report
por: Mao, Xiaoyun, et al.
Publicado: (2019)

Correlation between Androgen Receptor Expression in Luminal B (HER–2 Negative) Breast Cancer and Disease Outcomes
por: Yang, Fan, et al.
Publicado: (2022)

PROGNOSTIC IMPACT OF LOW ESTROGEN AND PROGESTERONE POSITIVITY IN LUMINAL B (HER2 NEGATIVE) BREAST CANCER
por: Rajc, Jasmina, et al.
Publicado: (2018)

Prognostic parameters of luminal A and luminal B intrinsic breast cancer subtypes of Pakistani patients
por: Hashmi, Atif Ali, et al.
Publicado: (2018)

Protein kinase C targeting of luminal (T-47D), luminal/HER2-positive (BT474), and triple negative (HCC1806) breast cancer cells in-vitro with AEB071 (Sotrastaurin) is efficient but mediated by subtype specific molecular effects
por: Albert, Veruschka, et al.
Publicado: (2022)

A Nomogram for Predicting Liver Metastasis of Lymph-Node Positive Luminal B HER2 Negative Subtype Breast Cancer by Analyzing the Clinicopathological Characteristics of Patients with Breast Cancer
por: Yue, Yuhan, et al.
Publicado: (2022)

A mouse model for Luminal epithelial like ER positive subtype of human breast cancer
por: Kumar, MJ Mahesh, et al.
Publicado: (2007)

Quantum dot-based immunofluorescent imaging of Ki67 and identification of prognostic value in HER2-positive (non-luminal) breast cancer
por: Sun, Jin-Zhong, et al.
Publicado: (2014)

The prognostic value of quantitative analysis of CCL5 and collagen IV in luminal B (HER2−) subtype breast cancer by quantum-dot-based molecular imaging
por: Zhu, Yong-yun, et al.
Publicado: (2018)

Prognostic Relevance of Progesterone Receptor Levels in Early Luminal-Like HER2 Negative Breast Cancer Subtypes: A Retrospective Analysis
por: Diana, Anna, et al.
Publicado: (2022)

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer
por: Lipton, Allan, et al.
Publicado: (2013)

Luminal B subtype: A key factor for the worse prognosis of young breast cancer patients in China
por: Tang, Li-Chen, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_u63fuu7uvjjss8dpr4pcjmdcr7